Oligonucleotide-based sequence alteration in living cells is a substantial methodological challenge in gene therapy. Here, we demonstrate that using corrective single-stranded oligonucleotides (ssODN), high and reproducible sequence correction rates can be obtained. CHO cell lines with chromosomally integrated multiple copy EGFP reporter genes routinely show rates of 4.5% targeted sequence correction after transfection with ssODN. We demonstrate that the cell cycle influences the rates of targeted sequence correction in vivo, with a peak in the early S phase during ssODN exposure. After cell division, the altered genomic sequence is predominantly passed to one daughter cell, indicating that targeted sequence alteration occurs after the replication fork has passed over the targeted site. Although high initial correction rates can be obtained by this method, we show that a majority of the corrected cells arrest in the G2/M cell cycle phase, although 1-2% of the corrected cells form viable colonies. The G2/M arrest observed after targeted sequence correction can be partially released by caffeine, pentoxifylline or Gö 6976 exposure. Despite substantial remaining challenges, targeted sequence alteration based on ssODN increasingly promises to become a powerful tool for functional gene alterations. Gene Therapy (2005) 12, 546-551.
Various strategies have been developed to achieve therapeutic targeted gene repair, including small fragment homologous sequence 1,2 ssODN, [3] [4] [5] [6] triple helixforming oligonucleotides containing a reactive group, [7] [8] [9] bifunctional oligonucleotides based on a triple helixforming DNA recognition domain 10, 11 and branched oligonucleotides. 12 Although a general proof of principle for oligonucleotide-based sequence alteration appears to be established, the paradigm for oligonucleotide-based genome alteration remain largely unknown. 6 The central problem in studying this phenomenon are low rates of in vivo sequence correction rates in cell culture. Generally, observed sequence alteration rates on in vivo chromosomal templates in selected cell lines are in the range of 0.1%, 6 while correction rates in untransformed primary cells are substantially lower. [13] [14] [15] In the absence of a suitable selection system, such low rates allow only limited functional analysis, although Yoon and co-workers have recently suggested a selection system based on simultaneous targeting of two loci. 16 A further problem is the variety of model systems and assays that were used to measure targeted sequence correction which lead to confusing and often conflicting results. 6 Despite these obstacles, several consistent observations have been made: targeted sequence correction depends centrally on transcription, and ssODN that are complementary to the nontranscribed strand show in most cases substantially higher correction rates than ssODN complementary to the transcribed strand in both episomal and chromosomal assays. 17, 18 The involvement of transcription-coupled repair has therefore been suggested. Furthermore, the absence of MSH2, a protein involved in mismatch repair (MMR), has been shown to increase targeted sequence alteration rates in mouse embryonic stem (ES) cells. 13 The reason for this observation remains unclear, but a deficiency in the MMR machinery would increase the tolerance for a mismatch between ssODN and the target sequence, while a functional MMR could remove the mismatched base from the ssODN. Finally, in contrast to procaryotic systems, 19 a model based on the integration of a ssODN into the lagging strand during replication could not be established in mammalian cells using episomal assays. 20 To achieve high rates of ssODN-based sequence correction that would allow an improved tool for in vivo analysis; two CHO cell lines were created that contained multiple copies of a chromosomally integrated mutated EGFP (mEGFP-a and -b) reporter gene. Such a strategy was essential since the literature shows conflicting results between in vivo assays on chromosomal DNA, in vivo assays on episomal DNA and in vitro experiments carried out on cell extracts. 6 As seen in Figure 1 , CHOmEGFP-a and -b reporter cells showed significant rates of targeted sequence correction after ssODN exposure. After transfection of the CHO-mEGFP-a or CHOmEGFP-b reporter cells with ssODN (a2a and b2a), 4.5 and 0.35% cells, respectively, could routinely be obtained (n ¼ 30) that produced functional EGPF (Figures 1a, b  and 2a, b) . A flow cytometry analysis of CHO-mEGFP-a cells treated with a corrective ssODN (a2a, complementary to the nontranscribed strand) showed a distinct population of strongly green fluorescent cells (Figure 1a , right panel). ssODN allowed the introduction of sitespecific sequence alterations in the mEGFP target with high specificity. Control ssODN (actr1a) that did not contain a corrective mismatch showed no measurable background activity (Figure 1a, left panel) . Furthermore, sequencing of green cells derived from the CHOmEGFP-b cell line after transfection with ssODN revealed that in all cases the observed changes in the chromosomal template after ssODN exposure corresponded exactly to the sequence of the ssODN. Thus, using ssODN b2a that forms two mismatches when hybridized to the mEGFP-b reporter, both mismatched bases are altered in the chromosomal template. In no cases only one base, or alternative collateral bases changed (Figure 1c) . Interestingly, it was observed that sequence correction by ssODN tolerates well more than one mismatch with the chromosomal target. The ssODN that contained two adjacent corrective mismatches (ssODN a2a and b2a; Figure 2a , b) led consistently to higher sequence correction rates when compared to ssODN containing only one mismatch (ssODN a1a, b1a; pmEGFP-a contains a Tyr 66 (TAC) to Ser 66 (TCC) missense mutation in the pEGFP-c1 plasmid (Clontech, BD Biosciences) that renders the EGFP protein nonfluorescent, and a silent Lys 45 (AAG to AAA) diagnostic mutation. pmEGFP-b was prepared by inserting the EGFP-coding sequence from pEGFP-c1 into the pNRTIS-21 vector. 28 The pmEGFP-b construct contains a premature stop codon at Lys 41 (AAG) to stop 41 (TAG) that renders the EGFP protein nonfluorescent and the following silent point mutations: Gly 31 (GGC to GGA), Gly 33 (GGC to GGA), Gly 35 (GGC to GGA) and Gly 40 (GGC to GGA). The pmEGFP-a and pmEGFP-b constructs were stably transfected into CHO cells and individual clones were isolated after G418 selection (0.8 mg/ml). Clonal reporter cell lines were functionally selected by transfection with corrective ssODN (a2a and b2a) that contained a wild-type EGFP sequence. Quantitative Southern blot analysis established that CHO-mEGFP-a contained 60 copies of the reporter, while CHO-mEGFP-b contained 12 copies. For targeted sequence correction, cells were transfected in six-well plates (150 000 cells/well the day before transfection) with 4 mg ssODN and 8 ml Lipofectamine 2000 (Invitrogen)/well according to the manufacturer's instructions. Cells were incubated for 1 h with the transfection mix, followed by 24 h incubation without transfection mix before analysis by flow cytometry (100 000 cells). For sequencing, the EGFP region was PCR amplified from genomic DNA from sorted (FACS DiVa cell sorter, BD Biosciences) converted CHO-mEGFP-b cells and cloned into a sequencing vector by the TOPO TA cloning kit (Invitrogen). Quantification of green converted cells and cell cycle analysis were performed on a Parterc PAS flow cytometer (Partec GmbH) equipped with a 488 nm argon laser and a HBO lamp. Image acquisition was carried out with a Zeiss Axiovert 200M microscopy equipped with a Zeiss Axiocam HR color camera.
Functional sequence correction by ssODN PA Olsen et al Figure 2a , b), while more than three mismatches resulted in a reduction of the sequence correction frequencies (Figure 2b) .
CHO-mEGFP-a and CHO-mEGFP-b cell lines transfected with ssODN showed sequence correction only when they were transfected while they were dividing (Figure 3a, left panel) . If the cells were confluent at the time of transfection, no sequence correction could be detected (not shown). Therefore, the correlation between ssODN-based sequence correction and cell cycle stages was tested. CHO cells can efficiently be arrested in the G1/S phase by mimosine, a drug that reversibly inhibits both replication initiation and strand elongation. 21 After removing the drug, cells progress synchronically into the S and G2/M phase. 22 As seen in Figure 3a (right panel), cells kept in the G1/S phase by continuous exposure to mimosine before and after transfection with ssODN displayed no sequence correction. If cells were released from the G1/S arrest and transfected with ssODN (b2a) in intervals, sequence correction rates changed depending on the stage of the cell cycle. Correction frequencies increased 10-fold if the cells were transfected immediately after release from the G1/S arrest (Figure 3b, T0) . When the cells were transfected after they had progressed to the late S phase and G2/M phase, correction frequencies dropped to 0.57 and 0.32% (Figure 3b, T8 and T12, respectively). Cells arrested in the G2/M phase, by the microtubule-depolymerizing agent nocodazole, displayed correction rates similar to cells that had progressed to the S or G2/M phase (Figure 3b, right panel) . Control experiments with fluorescently labeled ssODN showed that uptake of ssODN did not alter significantly throughout cell cycle progression (not shown). This demonstrates that the observed alterations are not due to differential uptake of the ssODN but rather reflect cell cycle-specific changes in the capability of undergoing sequence alteration. The preferred stage for targeted sequence correction is thus cells in the S phase, but correction can also take place in the G2/M phase. No measurable correction was taking place when cells were arrested in the G1 phase. Ferrara and Kmiec 23 have recently reported increased ssODN-mediated sequence correction rates in the late S phase/early G2 phase. In their system, DLD-1 cells were pretreated with camptothecin, a drug that induces DNA strand breaks with a subsequent shift of the cells towards the late S/early G2 cell cycle phase before ssODN transfection.
To further confirm the importance of the cell cycle in targeted sequence correction, the fate of corrected cells was analyzed. If targeted sequence correction can occur in the G1 phase, one would expect that the alteration would be passed on to both daughter cells after replication and cell division. However, if the repair process occurred during or after replication, it would be expected that only one daughter cell would contain the sequence-corrected template. We therefore followed the intensity of EGFP fluorescence in corrected cells after cell division. Figure 3c and d shows that from 80% of the corrected cells only one daughter cell maintained strong EGFP staining, while the other daughter cell displayed decreased fluorescence intensity. In CHO cells stably expressing wild-type EGFP, the fluorescence intensity did not differ between daughter cells after cell division (Figure 3d, filled bars) . The reduction of fluorescence in one of the daughter cells again supports a scenario where targeted sequence alteration occurs predominantly in the S or G2/M phase.
Stable colonies harboring the nucleotide change introduced by ssODN could be routinely established. Nevertheless, the number of colonies that emerged did not correspond to the initial number of green corrected cells. Over a period of 4 days, the number of green cells dropped by 40-60% every 24 h, independent on the analyzed reporter cell line (Figure 4a) . From the total amount of green cells detected 24 h after ssODN transfection, only 1-2% was capable of forming viable colonies. The majority of the initially green cells did not divide, but started to round up and eventually detached from the surface, although they did not loose their green fluorescence (Figure 4b) . To determine at which stage of the cell cycle the majority of converted cells remained, 0 -tgg gac tgg agg ccg cac gtc acg aag-5 0 ; a1a 3 0 -tgg gac tgg atg ccg cac gtc acg aag-5 0 ; a2a 3 0 -tgg gac tgg ata ccg cac gtc acg aag-5 0 ; a3a 3 0 -tgg gac tgc atg ccg cac gtc acg aag-5 0 ; a4a 3 0 -tgg gac tgc ata ccg cac gtc acg aag-5 0 ; bctr1a 3 0 -tgg atg cct atc gac tgg gac ttc aag t-5 0 ; b1a 3 0 -tgg atg cct ttc gac tgg gac ttc aag t-5 0 ; b2a 3 0 -tgg atg ccg ttc gac tgg gac ttc aag t-5 0 ; b3a 3 0 -tgg atg ccg tgc gac tgg gac ttc aag t-5 0 ; b4a 3 0 -tgg atg ccg tgg gac tgg gac ttc aag t-5 0 (underlined bases indicates positions of mismatches). . Cells were arrested at the G1/S border by the procedure described. 21 Briefly, the cells were grown for 48 h in media containing 0.2% FBS, then incubated for 24 h in growth media containing 5% FBS and 100 mM mimosine (Sigma). The cells were transfected (1 h) in media containing mimosine. After one wash with PBS, the cells were either kept in the G1 phase by continued incubation with mimosine or allowed to synchronically progress into the cell cycle by removal of mimosine. For cell cycle analysis, the cells were ethanol fixed, DAPI stained and analyzed for DNA content by flow cytometry. Cells were arrested at the G2/M phase by overnight incubation with nocodazole (0.5 mg/ml) (Sigma-Aldrich). For caffeine (Sigma-Aldrich) treatment, the cells were incubated in 2 mM caffeine 2 h before and 3 h after ssODN transfection.
Functional sequence correction by ssODN PA Olsen et al cells either escapes from the arrest, or does not enter the G2/M arrest after targeted sequence alteration. However, most corrected cells remain in the G2/M arrest. It is known that cells can respond to DNA damages that arise during or after replication by the activation of the ATM/ ATR kinase-dependent G2/M checkpoint. 24 We therefore tested the impact of caffeine and pentoxifylline that target ATM/ATR, and of Gö 6976 that inhibits with high specificity the ATM/ATR downstream mediators Chk1 and/or Chk 2. 25 Compared to caffeine and pentoxyfylline, Gö 6976 has a greater selectivity in abrogating DNA damage-induced cell cycle arrest. 25 If an ATM/ATR-dependent G2/M arrest was responsible for the failure of most green corrected cells to progress through mitosis, exposure of the cells to either caffeine, pentoxifylline or Gö 6976 would be expected to release cells from a G2/M block. 25, 26 As seen in Figure 5a and b, when CHO-mEGFP-b cells were transfected with ssODN b2a, 5% of the green corrected cells had undergone cell division 24 h after transfection. However, if the cells received an overnight exposure of 3 mM caffeine, or 3 mM pentoxifylline, 15 and 12% of the corrected cells, respectively, entered visible division (Figure 5a, b) . The strongest effect on the G2/M arrest was seen after treatment with 150 nM of the Chk1 inhibitor Gö6976. When cells were treated overnight with Gö 6976, 30% fluorescent dividing cells were observed (Figure 5a, b) . Treatment of cells with caffeine, pentoxifylline or Gö 6976 did not give rise to increased number of corrected cells forming viable colonies (not shown). This was not surprising since it is known that abrogation of a G2 cell cycle arrest (preferentially in p53-defective cells) by these drugs drives the cells through a lethal mitosis. 27 The effective G2/M block and low rate of cells that processed into normal cell division after ssODN 
